Antimicrobial Resistance Diagnostics Market Growth & Trends
The global antimicrobial resistance diagnostics market size is expected to reach USD 6.7 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 6.2% from 2022 to 2030. The increased risk of developing drug-resistant bacterial infections, especially in healthcare facilities, and increasing government & non-government bodies’ efforts to combat the threat of AMR are the major factor contributing to market growth. In addition, various strategic initiatives undertaken by leading market players to manage antimicrobial resistance are also contributing to market expansion. For instance, in March 2021, bioMerieux and GIZ collaborated to support the Nigerian center for disease control to strengthen the fight against AMR.
The rising adoption of rapid testing and PoC tests for drug-resistant bacterial infections is anticipated to augment the market over the projected period. Moreover, leading market players such as Danaher, Abbott, and others have a robust product portfolio of rapid diagnostic tests for antimicrobial-resistant infections. Furthermore, the increasing involvement of non-government bodies such as AMR Industry Alliance is assisting regulatory bodies to make strategies to boost the development of diagnostic solutions to manage antimicrobial resistance.
Increasing funding for the development of novel and automated test solutions for the diagnosis of antimicrobial-resistant infections is anticipated to boost market growth over the forecast period. For instance, in May 2022, the European Investment Bank funded more than USD 24 million to POCARED Diagnostics for the R&D of fully automated testing of microbial diseases. POCARED Diagnostics is involved in the development of novel microbiology tests that can provide results within hours.
Antimicrobial resistance is expected to rise in the coming years. Hence, demand for accurate & fast testing options is expected to increase for the effective management and progression monitoring of antimicrobial resistance. According to the CDC, the annual direct healthcare expenditure of antimicrobial resistance is around USD 20 billion in the U.S. High cost of disease management is driving the demand for rapid tests for the diagnosis of infections at an early stage.
Key market players are continuously involved in the development of novel tests to strengthen their market position. Moreover, other strategies such as acquisitions, partnerships, and collaborations are also adopted by leading players to expand their product portfolio in different parts of the globe. For instance, in August 2022, Accelerate Diagnostics and BD announced a collaboration to combat the threat of antimicrobial resistance. As per the deal, BD will provide Accelerate Diagnostics rapid diagnostic solutions for antibiotics-associated resistance to its vast customers.
Request a free sample copy or view report summary: Antimicribial Resistance Diagnostics Market Report
Antimicrobial Resistance Diagnostics Market Report Highlights
PCR held the largest share of the technology segment in 2021 owing to the high penetration and technological advancements
Based on pathogen segment, the Methicillin resistant staphylococcus aureus accounted for the largest share in 2021 due to the high incidence rate of MRSA infections and the surge in product launches
In end-user, the hospital segment was the highest revenue contributor in 2021 because of higher patient admissions and high incidence of bacterial infections
In Asia Pacific, the market is expected to exhibit the fastest growth over the forecast period due to the rising investments by market players and increasing research activities in the region
Access Press Release@ https://www.grandviewresearch.com/press-release/global-antimicrobial-resistance-diagnostics-market
Antimicrobial Resistance Diagnostics Market Segmentation
Grand View Research has segmented the global antimicrobial resistance diagnostics market based on technology, pathogen, end user, and region:
Antimicrobial Resistance Diagnostics Technology Outlook (Revenue, USD Million, 2018 - 2030)
Microbiology Culture
Immunoassay
PCR
NGS
Mass Spectrometry
Rapid & Point of Care
Others
Antimicrobial Resistance Diagnostics Pathogen Outlook (Revenue, USD Million, 2018 - 2030)
Drug Resistant Streptococcus Pneumoniae (DRSP)
Drug Resistant Campylobacter (DRC)
Clostridium Difficile (CD)
Methicillin Resistant Staphylococcus Aureus (MRSA)
Drug Resistant Neisseria Gonorrhoeae (DRNG)
Drug Resistant Salmonella (DRNTS)
Others
Antimicrobial Resistance Diagnostics End-user Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals
Diagnostic Laboratories
Pharmaceutical & Biotechnology Companies
Others
Antimicrobial Resistance Diagnostics Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Asia Pacific
Japan
China
India
South Korea
Australia
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
List of Key Players of Antimicrobial Resistance Diagnostics Market
bioMerieux
F. Hoffmann-La Roche Ltd.
Abbott
Hologic, Inc.
BD
Danaher
Accelerate Diagnostics, Inc.
Molsid
Vela Diagnostics
Visby Medical, Inc.
OpGen
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
No comments:
Post a Comment